title: Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma.
abstract: OBJECTIVE
  To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma.
  
  
  METHODS
  A 2% ibopamine eye drop was topically administered 3 times daily during 24 weeks.
  
  
  RESULTS
  Seventeen patients were included. Nine patients were able to continue their treatment up to 24 weeks; their mean intraocular pressure increase was 2.11 mmHg (SE, 0.56; 95% confidence interval, 0.96 to 3.23; P < 0.0005) in comparison with baseline values. Eight patients stopped using ibopamine before 24 weeks because of complains of follicular conjunctivitis or irritation without clinically observable conjunctivitis. In these patients a comparable increase in intraocular pressure was observed up to treatment discontinuation.
  
  
  CONCLUSIONS
  This study confirms that the use of topical ibopamine may result in a sustained increase in intraocular pressure of >2 mmHg in the majority of patients, but was only well tolerated in half of them. There may only be a few patients, however, who will clinically benefit from this rise in intraocular pressure. A better formulation or method of administration would be needed.
authors: The Rotterdam Eye Hospital, Rotterdam, the Netherlands.
authors: Elizabeth
authors: E
authors: Ganteris-Gerritsen
authors: Luana Cahya
authors: LC
authors: Ugahary
authors: Jan
authors: J
authors: Jansen
authors: Paul G H
authors: PG
authors: Mulder
authors: Adam F
authors: AF
authors: Cohen
authors: Jan C
authors: JC
authors: van Meurs
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use*; D015807:Eye Injuries, Penetrating / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009184:Mydriatics / Q000627:therapeutic use; D015814:Ocular Hypotension / Q000188:drug therapy* / Q000209:etiology; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D012163:Retinal Detachment / Q000150:complications* / Q000601:surgery; D014065:Tonometry, Ocular; D014605:Uveitis / Q000150:complications*; D057586:Vitreoretinal Surgery / Q000009:adverse effects*
chemical_list: D018491:Dopamine Agonists; D009184:Mydriatics; D009883:Ophthalmic Solutions; C023487:ibopamine; D003846:Deoxyepinephrine